CD8A and neoplasm: Moreover, SD-208, a novel inhibitor of TGFBR1, induces the infiltration of immune cells, including macrophages, CD8+ T cells, and NK cells, to enhance the immunogenicity of glioma cells and inhibit tumour progression [156].